☆ 4.8 Article

Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection

FRONTIERS IN IMMUNOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection

Patricia Perez et al.

Summary: Researchers developed an optimized COVID-19 vaccine candidate using a modified vaccinia virus Ankara vector, which expressed a full-length prefusion-stabilized SARS-CoV-2 spike protein. The vaccine showed enhanced immunogenicity and efficacy against SARS-CoV-2 in animal models, making it a promising candidate for clinical trials.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Medicine, General & Internal

Intranasal COVID-19 vaccines: From bench to bed

Aqu Alu et al.

Summary: Currently licensed COVID-19 vaccines are administered intramuscularly and fail to activate mucosal immunity, which contributes to the inability to prevent upper respiratory tract infection. The demand for the next generation of COVID-19 vaccines that can induce both mucosal and systemic immune responses has led to the investigation of intranasal vaccination. Several intranasal vaccines against SARS-CoV-2 are currently under intensive investigation, with 12 candidates in clinical trials at different phases.

EBIOMEDICINE (2022)

添加到收藏夹

Article Immunology

Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice

Adrian Lazaro-Frias et al.

Summary: The MVA-CoV2-S vaccine candidate protected transgenic mice from a lethal dose of SARS-CoV-2 through two doses, inducing high levels of antibodies and providing long-term memory immune responses. The vaccine showed efficacy in preventing virus replication, reducing lung pathology, and inducing protective antibody responses against the parental virus and variants of concern.

NPJ VACCINES (2022)

添加到收藏夹

Article Immunology

Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates

Flavia Chiuppesi et al.

Summary: Research shows that the COH04S1 vaccine provides effective protection against SARS-CoV-2 in animal models through different vaccination routes and dose regimens. It induces specific immune responses, including cross-neutralizing antibodies, and protects against symptoms and lung damage caused by viral challenge. Additionally, the vaccine also triggers strong immune responses and antiviral reactions in non-human primates.

NPJ VACCINES (2022)

添加到收藏夹

Article Immunology

Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2

Petra Mooij et al.

Summary: This study demonstrates that a modified vaccinia virus Ankara (MVA) vector expressing a full-length SARS-CoV-2 spike (S) protein (MVA-S) vaccine has good safety and high immunogenicity in rhesus macaques. Vaccination with MVA-S can induce neutralizing antibodies against SARS-CoV-2 and its variants, reduce viral loads, and alleviate lung pathology caused by the disease. The findings support the potential use of MVA-S as a vaccine for SARS-CoV-2 in clinical trials.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Immunology

MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters

Robbert Boudewijns et al.

Summary: This study reports the potent immunogenicity and efficacy of a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector in hamsters. The vaccine induced high levels of neutralizing antibodies against SARS-CoV-2 and its variants, and resulted in reduced viral RNA and infectious virus in the lungs of vaccinated hamsters. These findings support the potential use of MVA-S as a vaccine candidate for SARS-CoV-2.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1trial

Flavia Chiuppesi et al.

Summary: COH04S1 vaccine showed good tolerability and induced spike-specific and nucleocapsid-specific antibody and T-cell responses in healthy adults.

LANCET MICROBE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection

Jeffrey L. Americo et al.

Summary: Intranasal administration of a SARS-CoV-2 vaccine induces stronger immune responses compared to intramuscular administration, with higher levels of antibodies and specific T cells. Additionally, intranasal vaccination can prevent or rapidly eliminate SARS-CoV-2 infection.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

添加到收藏夹

Article Virology

COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice

Juan Garcia-Arriaza et al.

Summary: Two COVID-19 vaccines based on MVA vectors induced robust and polyfunctional T-cell responses and neutralizing antibody titers in mice, providing protection against SARS-CoV-2. The results demonstrate the full efficacy of MVA-based COVID-19 vaccines in animal models and support their translation to clinical use.

JOURNAL OF VIROLOGY (2021)

添加到收藏夹

Article Cell Biology

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Zijun Wang et al.

Summary: The IgA response to SARS-CoV-2 was characterized in a cohort of 149 convalescent individuals after COVID-19 diagnosis. IgA responses in plasma generally correlated with IgG responses, and B cells producing IgM, IgG, and IgA were derived from common progenitor cells. Notably, IgA dimers were found to be 15 times more potent than IgA monomers against SARS-CoV-2, suggesting their potential value for protection and vaccine efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Cell Biology

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin et al.

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Intranasal vaccine: Factors to consider in research and development

Haiyue Xu et al.

Summary: There are currently only a few intranasal vaccines approved for human use, mainly live attenuated influenza virus vaccines. Challenges exist in developing intranasal vaccines, including unique formulation considerations, the need for safe and effective mucosal vaccine adjuvants, and improved vaccine application devices. Preclinical animal models that can better predict intranasal vaccine performance in clinical trials are also crucial to increasing the success rate of intranasal vaccines.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2021)

添加到收藏夹

Article Immunology

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents

Berislav Bosnjak et al.

Summary: The study demonstrates that intranasal delivery of MVA-SARS-2-S effectively induces pulmonary spike-specific CD8(+) T cells, albeit with restricted production of neutralizing antibodies. Intranasal booster vaccine delivery is crucial for massive expansion of spike-specific CD8(+) T cells in systemic and lung tissues, as well as the development of Th1 - but not Th2 - CD4(+) T cells, with high levels of IgG and IgA anti-spike antibodies capable of neutralizing all current SARS-CoV-2 variants of concern.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity

Carlos del Fresno et al.

Summary: The bacterial mucosal immunotherapy MV130 provides protection against SARS-CoV-2 infection and enhances the immunogenicity of COVID-19 vaccines. Studies have shown that prophylactic intranasal administration of MV130 boosts specific immune responses across different vaccine candidates and administration routes, including CD8(+)-T cell activation and mucosal IgA antibody production.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge

Clement A. Meseda et al.

Summary: Using MVA vectors expressing SARS-CoV-2 S as vaccines provides protection in adult Syrian hamsters, demonstrating the utility of this animal model in evaluating candidate SARS-CoV-2 vaccines.

NPJ VACCINES (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Shipo Wu et al.

Summary: The study evaluated the safety and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine in adults without COVID-19 from China. It found that the aerosol vaccine was well tolerated, and two doses elicited neutralising antibody responses similar to one dose of intramuscular injection. An aerosolised booster vaccination at 28 days after the first intramuscular injection induced strong IgG and neutralising antibody responses. The efficacy and cost-effectiveness of aerosol vaccination should be evaluated in future studies.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters

Rakesh Kulkarni et al.

Summary: SARS-CoV-2 causes severe illness and mortality, highlighting the urgent need for vaccines. The development of stable lyophilized vaccines is crucial for global vaccination to combat the virus and potential variants. Additionally, promising candidate vaccines based on viral strains have shown to induce strong immune responses in animal models, providing hope for future development.

PLOS ONE (2021)

添加到收藏夹

Article Cell Biology

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models

Neeltje van Doremalen et al.

Summary: Intranasal vaccination with ChAdOx1 nCoV-19/AZD1222 reduced viral loads in nasal swabs in vaccinated macaques and hamsters challenged with SARS-CoV-2, indicating potential for further investigation as a vaccination route for COVID-19 vaccines.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Cell Biology

A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters

Traci L. Bricker et al.

Summary: The study found that intranasal administration provides superior protection against SARS-CoV-2 infection and inflammation in the upper respiratory tract compared to intramuscular injection, reducing weight loss, viral infection, and lung pathology. Therefore, intranasal delivery of ChAd-SARS-CoV-2-S candidate vaccine is supported for preventing SARS-CoV-2 infection.

CELL REPORTS (2021)

添加到收藏夹

Article Microbiology

DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist

Michel Thepaut et al.

Summary: The study reveals that C-type lectin receptors (CLRS) can bind to the spike envelope protein of SARS-CoV-2, and DC-SIGN and L-SIGN among them can promote virus trans-infection. This discovery identifies a new mechanism for enhancing viral spread.

PLOS PATHOGENS (2021)

添加到收藏夹

Article Cell Biology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

Ahmed O. Hassan et al.

Summary: The study demonstrates the immunogenicity and protective efficacy of an intranasally administered vaccine in non-human primates, showing that it induces neutralizing antibodies and T cell responses, effectively limiting or preventing infection of SARS-CoV-2 in the respiratory tract.

CELL REPORTS MEDICINE (2021)

添加到收藏夹

Article Infectious Diseases

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Victor M. Corman et al.

EUROSURVEILLANCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A new coronavirus associated with human respiratory disease in China

Fan Wu et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Virology

Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples

Alessandro Manenti et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Virological assessment of hospitalized patients with COVID-2019

Roman Woelfel et al.

NATURE (2020)

添加到收藏夹

Article Public, Environmental & Occupational Health

Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection

Gregory Brett Moreau et al.

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)

添加到收藏夹

Article Immunology

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins

Jose Maria Diez et al.

IMMUNOTHERAPY (2020)

添加到收藏夹

Article Immunology

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Emma S. Winkler et al.

NATURE IMMUNOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Lisa H. Tostanoski et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform

Flavia Chiuppesi et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Medicine, General & Internal

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial

Zita-Rose Manjaly Thomas et al.

PLOS MEDICINE (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Immune responses after live attenuated influenza vaccination

Kristin G. -I. Mohn et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Sterilizing immunity to influenza virus infection requires local antigen-specific T cell response in the lungs

Avijit Dutta et al.

SCIENTIFIC REPORTS (2016)

添加到收藏夹

Article Immunology

Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of Macaques

A. D. White et al.

CLINICAL AND VACCINE IMMUNOLOGY (2013)

添加到收藏夹

Article Medical Laboratory Technology

High-Yield RNA-Extraction Method for Saliva

Pratibala Pandit et al.

CLINICAL CHEMISTRY (2013)

添加到收藏夹

Review Immunology

Clinical applications of attenuated MVA poxvirus strain

Carmen Elena Gomez et al.

EXPERT REVIEW OF VACCINES (2013)

添加到收藏夹

Article Immunology

Multiple Infections with Seasonal Influenza A Virus Induce Cross-Protective Immunity against A(H1N1) Pandemic Influenza Virus in a Ferret Model

Karen L. Laurie et al.

JOURNAL OF INFECTIOUS DISEASES (2010)

添加到收藏夹

Article Multidisciplinary Sciences

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions

Juan Garcia-Arriaza et al.

PLOS ONE (2010)

添加到收藏夹

Article Multidisciplinary Sciences

Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic

Max Corbett et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

添加到收藏夹

Review Biochemistry & Molecular Biology

Mucosal immunity and vaccines

J Holmgren et al.

NATURE MEDICINE (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.